GNOM


Genomics & Biotechnology ETF

Reasons to Consider GNOM

High Growth Potential

Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1

Structural Tailwinds

Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 47% compound annual growth rate from 2022-2028.2

Targeted Exposure

GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

1International Society for Cell and Gene Therapy, Feb 2019
2Evaluate Pharma, Nov 2023

Key Information As of 03/01/24

Inception Date 04/05/19
Total Expense Ratio 0.50%
Net Assets $101.11 million
NAV $12.29

ETF Summary

The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

ETF Objective

The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

Trading Details As of 03/01/24

Ticker GNOM
B3 Trading Code BGNO39
Bloomberg Index Ticker SOLGNOM
CUSIP 37954Y434
ISIN US37954Y4347
Primary Exchange Nasdaq
Shares Outstanding 8,230,000
Number of Holdings 41
30-Day Median Bid-Ask Spread 0.17%

Distributions As of 03/01/24

30-Day SEC Yield -0.18%
Distribution Frequency Semi-Annually

ETF Prices As of 03/01/24

NAV $12.29 Daily Change $0.28 2.33%
Market Price $12.29 Daily Change $0.31 2.59%

Performance History

Cumulative Returns (as of 02/29/24)
1 Month 6 Months YTD 12 Months 24 Months Since Inception Inception Date
Return GNOM 11.62% 7.05% 3.80% -4.61% -25.24% -21.27% 04/05/19
Returns (as of 02/29/24)
Return GNOM Return Index
Since Inception -21.27% -19.41%
12 Months -2.28% -1.25%
24 Months -22.79% -22.17%
Last 60 Trading Days 12.43% 12.38%
Last 75 Trading Days 27.62% 27.77%
Monthly Returns (through 02/29/24)
Return GNOM Return Index
Mar 2024 0.00% 0.00%
Feb 2024 11.62% 11.55%
Jan 2024 -7.01% -6.90%
Dec 2023 11.12% 11.12%
Nov 2023 17.53% 17.71%
Oct 2023 -12.70% -12.66%
Sep 2023 -9.53% -9.44%
Aug 2023 -8.41% -8.28%
Jul 2023 1.22% 1.27%
Jun 2023 -0.83% -0.71%
May 2023 -0.40% 0.01%
Apr 2023 -0.32% -0.36%
Mar 2023 -2.40% -2.28%
Feb 2023 -7.07% -7.73%
Jan 2023 7.02% 7.13%
Dec 2022 -5.87% -5.89%
Nov 2022 2.37% 2.43%
Oct 2022 4.96% 5.00%
Sep 2022 -9.67% -9.59%
Aug 2022 -2.51% -2.52%
Jul 2022 16.09% 16.12%
Jun 2022 2.26% 2.22%
May 2022 -6.13% -5.96%
Apr 2022 -17.99% -18.04%
Mar 2022 -3.17% -3.15%

Total returns take into account management, administration and fees and other costs automatically deducted from the fund's assets. Before investing, you may read the prospectus in the “FEES AND EXPENSES” section for more details.

NAV & Index Chart

Top Holdings As of 03/01/24

Net Assets (%) Ticker Name Country SEDOL Market Price ($) Shares Held Market Value ($)
6.53 NTRA NATERA INC United States BYQRG48 89.41 74,592 6,669,270.72
6.26 CRSP CRISPR THERAPEUTICS AG United States BDHF4K6 83.75 76,267 6,387,361.25
4.79 RARE ULTRAGENYX PHARM United States BJ62Z18 53.69 91,020 4,886,863.80
4.40 ARWR ARROWHEAD PHARMA United States BYQBFJ8 36.08 124,489 4,491,563.12
4.35 BEAM BEAM THERAPEUTICS INC United States BK6L288 39.84 111,590 4,445,745.60
3.94 A AGILENT TECHNOLOGIES INC United States 2520153 139.06 28,900 4,018,834.00
3.92 NTLA INTELLIA THERAPEUTICS INC United States BYZM6C2 32.66 122,566 4,003,005.56
3.73 RCKT ROCKET PHARMACEU United States BDFKQ07 30.53 124,627 3,804,862.31
3.62 MRNA MODERNA INC United States BGSXTS3 95.06 38,929 3,700,590.74
3.61 ILMN ILLUMINA INC United States 2613990 140.50 26,231 3,685,455.50
3.60 TXG 10X GENOMICS INC-CLASS A United States BKS3RS7 45.56 80,639 3,673,912.84
3.55 TECH BIO-TECHNE CORP United States BSHZ3Q0 74.38 48,763 3,626,991.94
3.51 SRPT SAREPTA THERAPEUTICS INC United States B8DPDT7 128.67 27,867 3,585,646.89
3.35 QGEN QIAGEN N.V. United States BMGBZP0 43.45 78,616 3,415,846.08
3.12 BMRN BIOMARIN PHARMAC United States 2437071 87.14 36,504 3,180,958.56
3.00 LEGN LEGEND BIOTECH CORP-ADR United States BMX9K07 65.53 46,665 3,057,957.45
2.86 MYGN MYRIAD GENETICS INC United States 2614153 22.18 131,556 2,917,912.08
2.82 VCYT VERACYTE INC United States BFTWZY0 24.00 120,139 2,883,336.00
2.80 ALNY ALNYLAM PHARMACE United States B00FWN1 152.61 18,739 2,859,758.79
2.79 BNTX BIONTECH SE-ADR United States BK6H543 90.94 31,373 2,853,060.62
2.34 RNA AVIDITY BIOSCIENCES INC United States BMWHPY1 20.11 118,927 2,391,621.97
2.29 1548 HK GENSCRIPT BIOTECH CORP Hong Kong BD9Q2J2 1.98 1,179,218 2,334,637.76
2.06 PACB PACIFIC BIOSCIEN United States B4N8MH9 5.19 404,847 2,101,155.93
1.82 SANA SANA BIOTECHNOLOGY INC United States BMFJJ97 11.27 164,669 1,855,819.63
1.74 VRTX VERTEX PHARM United States 2931034 432.76 4,116 1,781,240.16
1.60 VIR VIR BIOTECHNOLOGY INC United States BK4PZ38 11.24 145,715 1,637,836.60
1.39 EDIT EDITAS MEDICINE INC United States BZ8FPH3 10.53 135,104 1,422,645.12
1.38 RGNX REGENXBIO INC United States BZ0G875 21.19 66,404 1,407,100.76
1.35 GILD GILEAD SCIENCES INC United States 2369174 72.31 19,005 1,374,251.55
1.14 VERV VERVE THERAPEUTICS INC United States BNKGXX2 16.29 71,464 1,164,148.56
1.02 CDNA CAREDX INC United States BP3YM74 12.01 86,574 1,039,753.74
0.97 CRBU CARIBOU BIOSCIENCES INC United States BNYJR68 7.79 126,977 989,150.83
0.86 ALLO ALLOGENE THERAPEUTICS INC United States BFZNYB7 4.94 177,646 877,571.24
0.72 FLGT FULGENT GENETICS INC United States BYQBFQ5 23.24 31,743 737,707.32
0.61 LYEL LYELL IMMUNOPHARMA INC United States BN6MB18 3.07 201,751 619,375.57
0.50 4974 JP TAKARA BIO INC Japan B03ML21 6.65 76,677 510,243.62
0.43 PSTX POSEIDA THERAPEUTICS INC United States BJ4SF41 4.13 106,721 440,757.73
0.41 TSVT 2SEVENTY BIO INC United States BMTXV88 5.64 74,522 420,304.08
0.39 QURE UNIQURE NV United States BJFSR88 5.59 70,491 394,044.69
0.26 BLUE BLUEBIRD BIO INC United States BBFL7S1 1.57 172,855 270,518.08
0.15 E SCILEX HOLDING RESTRICTED United States 9A80I96 0.67 226,071 150,902.11
0.08 CASH United States 1.00 81,623 81,622.95
0.00 JAPANESE YEN United States 0.01 -1 -0.01
-0.05 OTHER PAYABLE & RECEIVABLES United States 1.00 -53,847 -53,846.77
Holdings are subject to change. "Cash" denotes U.S. dollars.

Sector Breakdown As of 01/31/24

Sector Weight (%)
Health Care 92.6
Energy 7.4

Source: AltaVista Research, LLC

Country Breakdown As of 01/31/24

Country Weight (%)
United States 77.9
Italy 7.4
Switzerland 5.1
Netherlands 3.9
Germany 3.0
China 2.0
Japan 0.7

Source: AltaVista Research, LLC

ETF Characteristics As of 02/29/24

Return on Equity -14.90%
Weighted Avg. Market Cap 16,299 M
2023 2024
Price-to-earnings -17.72 -21.83
Price-to-book value 3.01 3.56

Source: AltaVista Research, LLC

ETF Risk Stats As of 01/31/24

Versus Beta
S&P 500 1.08
MSCI EAFE 0.95
MSCI Emg. Mkts 0.83
Standard Deviation 28.20%

Source: AltaVista Research, LLC

TERMS OF USE

Global X Brasil Gestora de Investimentos Ltda. (“Global X Brasil”) is an asset manager authorized by the Brazilian Securities and Exchange Commission (“CVM”), constituted in the form of CVM Resolution No. 21/2021. Investing involves risks. The material on this site is for informational purposes only and does not constitute investment advice, recommendation, offer or solicitation to buy or sell any securities, funds, or strategies to any person in any jurisdiction in which an offer, solicitation, purchase, or sale would be illegal under the securities laws of such jurisdiction. Opinions expressed here are subject to change without notice. Reliance upon the information contained in this material is at the sole discretion of the reader. No securities regulator has confirmed the accuracy of any information contained herein. Access to the information on this site or the use of the services or information provided herein is prohibited by any person or entity in any jurisdiction or country where such distribution or use is contrary to local law, rules, or regulation. Investment in index funds (ETFs) involves risks, including detachment from the benchmark index and related to the liquidity of shares in the secondary market. Investment funds managed by Global X Brasil use strategies that can result in significant equity losses for their quota holders. Global X Brasil, its partners and employees are exempt of responsibility for any damages resulting directly or indirectly from the use of the information contained on this website.

FOR EVALUATION OF THE PERFORMANCE OF AN INVESTMENT FUND, IT IS RECOMMENDED THE ANALYSIS OF AT LEAST 12 (TWELVE) MONTHS. INVESTMENT FUNDS DO NOT HAVE A GUARANTEE FROM THE ADMINISTRATOR, THE MANAGER, ANY INSURANCE MECHANISM OR CREDIT GUARANTEE FUND – FGC. INVESTMENTS IN FINANCIAL AND CAPITAL MARKETS ARE SUBJECT TO RISKS OF LOSS GREATER THAN THE TOTAL VALUE OF INVESTED CAPITAL. PAST PROFITABILITY DOES NOT REPRESENT A GUARANTEE OF FUTURE PROFITABILITY THE PROFITABILITY DISCLOSED IS NOT NET OF TAXES. READ THE PROSPECTUS, THE FORM OF COMPLEMENTARY INFORMATION, SHEET OF ESSENTIAL INFORMATION AND THE REGULATION BEFORE INVESTING. DESCRIPTION OF THE ANBIMA TYPE AVAILABLE IN THE FORM OF COMPLEMENTARY INFORMATION.

Back to Top